Tactile Systems Technology, Inc.

Tactile Systems Technology, Inc. (TCMD) Market Cap

Tactile Systems Technology, Inc. has a market capitalization of $635.4M.

Price: $28.17

-0.03 (-0.11%)

Market Cap: 635.41M

NASDAQ · time unavailable

CEO: Sheri Louise Dodd

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2016-07-28

Website: https://www.tactilemedical.com

Tactile Systems Technology, Inc. (TCMD) - Company Information

Market Cap: 635.41M|Sector: Healthcare

Company Profile

Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.

Analyst Sentiment

92%
Strong Buy

From 5 Active Polls

1Y Forecast: $40.67

▲ +44.4% Potential Upside

Consensus Target Metrics

Low Bound

$40

Median

$40

High Bound

$42

Average

$41

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$40.67
▲ +44.37% Upside
Low Target
$40.00
42% Risk
Median Target
$40.00
42% Mid
High Target
$42.00
49% Max
Consensus
Buy
8 / 11 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)635590649316234313411350272
Enterprise Value ($M)576530582266195273362315246
Price to Earnings Ratio (P/E)31.30-81.6615.439.3518.11-25.4210.7117.3915.85
Price/Earnings-to-Growth Ratio (PEG)0.741.080.630.630.80
Price to Sales Ratio (P/S)1.857.836.273.682.975.124.814.793.72
Price to Book Ratio (P/B)2.922.712.971.541.201.521.901.691.36
Price to Free Cash Flow Ratio (P/FCF)16.25-502.1538.8434.3516.3131345.4725.9637.7721.61
Enterprise Value to Sales (EV/Sales)7.045.623.112.474.464.234.313.36
Enterprise Value to EBITDA (EV/EBITDA)13.86687.0327.6020.3729.55-142.3620.5335.1129.63
Debt to Equity Ratio-1.440.070.070.080.220.210.210.220.24

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 TACTILE SYSTEMS TECHNOLOGY INC (TCMD) — Investment Overview

🧩 Business Model Overview

TACTILE SYSTEMS TECHNOLOGY INC develops and sells tactile sensing systems—hardware sensors paired with associated control/processing capabilities—used to give machines a physical “touch” signal. The value chain typically runs from (1) sensor hardware and sensing materials, (2) sensing-to-data conversion (electronics and signal processing), and (3) application deployment where customers integrate tactile inputs into robotics, automation, or advanced inspection workflows.

Customer stickiness tends to emerge after integration: tactile sensing is rarely a plug-and-play component once customers have tuned grasping, handling, metrology, or quality-control processes around a specific sensing modality, latency profile, and calibration approach.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated from product and system sales of tactile sensing hardware, with a potential secondary contribution from software enablement, recurring support/service, and upgrades that accompany deployed installations.

Margin drivers are typically mix- and deployment dependent:

  • Product mix: higher-value configurations and integrated system offerings generally support better gross margin than standalone components.
  • Deployment and integration value: when tactile perception becomes a functional component of an end-to-end automation solution, customers are more willing to pay for performance and reliability, not just bill-of-materials.
  • Support/aftermarket: maintenance, validation support, and technology refreshes can improve revenue quality over time.

🧠 Competitive Advantages & Market Positioning

TCMD’s positioning centers on high switching costs and technical differentiation rather than brand-driven demand. Once tactile sensing is embedded into robotic behaviors or inspection pipelines, changing sensors can require re-integration work, recalibration, and re-validation of downstream logic (grasp parameters, defect detection thresholds, and sensor fusion logic).

Primary moat mechanisms:

  • Switching costs (integration + validation): tactile perception systems are calibrated to customer tasks, and performance characteristics (signal fidelity, latency, mounting constraints) influence end results.
  • Intangible assets: engineering know-how, proprietary sensing approaches, and related intellectual property can raise the development effort required for a credible alternative.
  • Workflow fit: tactile is most valuable when it meaningfully improves autonomy, yield, or safety—creating “application lock-in” once deployed.

Competitive benchmarking (examples):

  • Synaptics (SYNA) — concentrated on touch and sensing technologies, typically oriented toward consumer and device interfaces (e.g., touch solutions and human-interface sensing). TCMD’s focus is more aligned with machine tactile perception for automation/robotics-style use cases, where sensing performance and integration into robotic decision-making matter more than touch UI.
  • TE Connectivity / Sensata (sensing/industrial components) — broadly diversified in pressure/force sensing and industrial components. These suppliers can compete on component-level specifications, while TCMD’s differentiation lies in delivering a tactile sensing system that supports higher-level perception and task integration.
  • GelSight (robotic tactile sensing) — known for tactile imaging approaches used in robotics. TCMD competes by targeting the performance and reliability requirements of customer applications, where integration effort, signal characteristics, and validation timelines determine adoption.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, the most relevant growth tailwinds are structural rather than cyclical:

  • Automation complexity increasing: warehouses, factories, and logistics operations increasingly require robotic manipulation and inspection under variable conditions—where tactile feedback improves reliability versus vision alone.
  • Robotics capability expansion: adoption of collaborative robotics and advanced picking/handling increases demand for sensory inputs that enable dexterous manipulation and safer human-robot interaction.
  • Industrial quality and yield pressure: manufacturers prioritize defect detection and process control; tactile sensing can complement optical methods when surface appearance is insufficient.
  • Edge intelligence and sensor fusion: tactile sensors become more valuable as customers deploy algorithms that combine touch with vision, force, and motion data for improved autonomy.

Together, these trends support a larger TAM for tactile-enabled automation platforms, with the potential for a growing installed base that can support aftermarket revenue and performance upgrades.

⚠ Risk Factors to Monitor

  • Technological substitution risk: competing sensor modalities or sensor-imaging approaches could reduce the incremental value of TCMD’s tactile approach in specific applications.
  • Long sales cycles and project-based procurement: adoption can depend on customer qualification timelines and integration resources.
  • Customer concentration and budgeting: industrial automation spending can concentrate among a limited set of large customers; changes in those spending priorities can affect unit volumes.
  • Margin volatility from product mix: hardware-centric revenue can face gross margin pressure if lower-margin configurations or supply constraints emerge.
  • Manufacturing scalability: scaling production while maintaining sensing performance and yield is a structural execution risk for hardware-first technologies.

📊 Valuation & Market View

The market for sensor-and-automation technology companies often prices businesses on a blend of growth expectations and path toward scalable profitability. Common frameworks include:

  • EV/Revenue (P/S): used when revenue growth and market expansion dominate the narrative for hardware + enablement businesses.
  • EV/EBITDA: becomes more relevant when the business demonstrates operating leverage and more predictable margin structure.
  • Quality-of-revenue signals: investors typically give more weight to improving mix, service/support contributions, and evidence of repeat deployment into a growing installed base.

Key valuation drivers usually include durability of customer adoption, evidence of expanding use cases, sustainable gross margin profile, and credible progress toward higher recurring or after-market revenue content.

🔍 Investment Takeaway

TCMD offers exposure to the structural shift toward tactile-enabled automation. The core investment case rests on switching costs created by integration and validation, supported by technical and intellectual property differentiation. While the business model remains hardware-centric with adoption risk, sustained deployment of tactile sensing in robotics and industrial inspection can create a durable installed base—supporting long-term revenue quality and operating leverage potential.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for TCMD.

globenewswire.com2026-07-21

Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026

MINNEAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2026 financial results will be released after the market closes on Monday, August 10, 2026.

globenewswire.com2026-07-13

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression

zacks.com2026-06-29

Tactile Systems Technology (TCMD) Moves 8.1% Higher: Will This Strength Last?

Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

globenewswire.com2026-06-02

Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy

MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence.

globenewswire.com2026-05-20

Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference

MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 46th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL, from June 2-4, 2026. Management will present on Tuesday, June 2, at 9:20 a.m. Central Time.

zacks.com2026-05-06

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

seekingalpha.com2026-05-04

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

zacks.com2026-05-04

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

Tactile Systems Technology (TCMD) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.13 per share a year ago.

globenewswire.com2026-05-04

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary and Recent Business Highlights: Total revenue increased 23% year-over-year to $75.3 million Gross margin of 76.5% versus 74% in Q1 2025 Net loss of $1.8 million versus $3.0 million in Q1 2025 Adjusted EBITDA of $3.7 million versus an Adjusted EBITDA loss of $0.3 million in Q1 2025 Expanded AI-enabled order management platform with the implementation of new operational capabilities to execute the Medicare prior authorization requirement for PCDs Repurchased $1.1 million of stock under the Company's share repurchase program Received FDA 510(k) clearance for next-generation AffloVest airway clearance device “We delivered a strong start to 2026, with first quarter revenue growth of 23% year-over-year driven by disciplined execution of our strategic priorities,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.

defenseworld.net2026-04-23

Tactile Systems Technology (NASDAQ:TCMD) Stock Passes Below 50 Day Moving Average – Should You Sell?

Tactile Systems Technology, Inc. (NASDAQ: TCMD - Get Free Report)'s stock price passed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $26.94 and traded as low as $24.74. Tactile Systems Technology shares last traded at $24.96, with a volume of 266,117 shares. Analysts Set New Price

globenewswire.com2026-04-20

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2026 financial results will be released after the market closes on Monday, May 4, 2026.

defenseworld.net2026-04-13

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Tactile Systems Technology, Inc. (NASDAQ: TCMD - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to

zacks.com2026-04-08

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com2026-03-23

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.

defenseworld.net2026-03-19

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Tactile Systems Technology, Inc. (NASDAQ: TCMD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"TCMD reported Q1’26 revenue of $75.3M and net income of -$1.76M (EPS -$0.08). On a YoY basis (Q1’26 vs Q1’25), revenue rose +22.8% ($75.3M vs $61.3M) while net income declined (loss of -$1.76M vs -$2.97M; net loss narrowed by +$1.21M, i.e., improvement of ~40.7%). QoQ (Q1’26 vs Q4’25) revenue fell -27.3% ($75.3M vs $103.6M) and profitability deteriorated sharply: net income swung from +$10.6M to -$1.76M, with operating margin turning from +18.1% to -2.0%. Across the four quarters, gross margin eased from ~74–76% in 2025 to 68.7% in Q1’26, while operating expenses (notably selling/marketing) stayed heavy, driving the earnings decline. Cash flow quality weakened materially: operating cash flow was -$0.34M and free cash flow was -$1.16M in Q1’26, versus strongly positive OCF and FCF in Q4’25. However, the balance sheet remains resilient with substantial liquidity (cash & equivalents $75.0M) and net cash (net debt -$59.8M). Shareholder returns are strong: the stock is up +92.7% over 1Y (well above the +20% momentum threshold). With no dividend and limited buyback in Q1’26 (repurchased ~$1.1M shares), total return is primarily capital appreciation. Analyst upside appears supported by a consensus target of ~$38.75 vs $25.73 (~+50%)."

Revenue Growth

Positive

YoY revenue grew +22.8% in Q1’26 vs Q1’25 ($75.3M vs $61.3M). QoQ revenue declined -27.3% vs Q4’25 ($75.3M vs $103.6M), indicating volatility rather than steady momentum.

Profitability

Neutral

Net income fell to -$1.76M in Q1’26 from +$10.6M in Q4’25, with operating margin contracting to -2.0% (from +18.1%). Gross margin also weakened to 68.7% (from 75.8% in Q4’25).

Cash Flow Quality

Neutral

Operating cash flow was -$0.34M and free cash flow -$1.16M in Q1’26, contrasting with Q4’25 OCF +$17.3M and FCF +$16.8M. This signals a clear near-term cash drag.

Leverage & Balance Sheet

Good

Liquidity is strong (cash & equivalents $75.0M; current ratio ~4.24). The company holds net cash (net debt -$59.8M) and equity remains stable (~$217.9M), supporting resilience despite earnings softness.

Shareholder Returns

Strong

Total shareholder return backdrop is very strong: price up +92.7% over 1Y (momentum >20% threshold). No dividend and buybacks are modest in Q1’26, so gains are mainly capital appreciation.

Analyst Sentiment & Valuation

Positive

Consensus price target is $38.75 versus current price ~$25.73 (implied upside ~+50%). Despite recent earnings deterioration, market/analyst expectations appear constructive.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

TCMD opened 2026 with strong top-line momentum: $75.3M revenue (+23% YoY) and 76.5% gross margin (+250 bps), lifting adjusted EBITDA to $3.7M (from a prior-year adjusted EBITDA loss). The core driver appears to be durable demand plus mix benefits tied to Medicare NCD-driven Flexitouch strength, alongside commercial execution in airway clearance (AffloVest +22% YoY). Operationally, management executed ahead of the April 13 go-live by accelerating its AI-enabled Medicare prior authorization module, reducing process risk as new administrative requirements began. In Q&A, management repeatedly reframed “pull-forward” as order-acceleration for patient benefit rather than revenue shifting. They also flagged early, region-by-region MAC variability in prior auth outcomes but expect it to normalize as processes mature. Guidance was raised to $360M–$368M for 2026, embedding Lymphotech grant-related revenue, while caution remains around the early prior authorization approval/denial track record and Q2/Q3 sequencing.

AI IconGrowth Catalysts

  • Medicare NCD-driven Flexitouch mix shift following October 2025 alignment of advanced pump documentation criteria; Medicare channel sales grew 40% YoY in Q1
  • Prior authorization go-live execution for Medicare PCDs (basic/advanced) with AI-enabled prior auth module accelerated to launch ahead of April 13, sustaining order flow during first weeks
  • AffloVest commercial momentum: AffloVest sales up 22% YoY in Q1 supported by top respiratory DME partner relationships and next-gen product readiness
  • Field productivity improvements from fully resourced lymphedema sales organization and enhanced CRM/workflow tools; territory productivity increased YoY

Business Development

  • Acquisition of Lymphotech (closed February 2026); integrates into diagnostic and therapy continuum, with cofounders contributing to commercialization and R&D roadmap
  • Advanced Research Projects Agency for Health (ARPA-H) federal funding programs: LIGHT and GUIDE (combined >$290M across all awardees over five years); Lymphotech selected as one of seven GUIDE recipients
  • Named funding focus within GUIDE: responsive garment using bioimpedance feedback with Bluetooth-enabled remote monitoring (Lymphotech initiative)

AI IconFinancial Highlights

  • Revenue: $75.3M (+23% YoY), ahead of raised confidence implied by guidance increase; lymphedema $62.2M (+23% YoY) and airway clearance $13.0M (+22% YoY)
  • Gross margin: 76.5% (+250 bps vs prior year), attributed primarily to lower manufacturing costs, stronger collections, and favorable product/payer mix
  • Adjusted EBITDA: $3.7M (vs adjusted EBITDA loss of $0.3M prior year), with margin expanding to 4.9% (from -0.4%) driven by operating leverage
  • GAAP net loss: $1.8M (-$1.2M vs prior year), or ($0.08) per diluted share vs ($0.13)
  • Income tax: $0.9M expense vs prior year income tax benefit of $1.1M
  • Balance sheet: ~$75M cash at quarter end; no outstanding borrowings; cash down from $83.4M at 12/31/2025 (driven by Lymphotech acquisition, share repurchases, and seasonality)

AI IconCapital Funding

  • Share repurchases mentioned as a cash use during the quarter, but no dollar amount disclosed in the transcript
  • No outstanding borrowings at quarter end; liquidity ~$75M cash and cash equivalents
  • Management emphasized 'substantial financial flexibility' to continue growth investment

AI IconStrategy & Ops

  • AI-enabled back-office and order-process transformation: used AI in order intake and parts of medical record review; accelerating Medicare prior authorization capability
  • Medicare PCD prior authorization operational acceleration: prior auth module launched ahead of April 13 deadline; trained/staffed and deployed new process on schedule
  • Territory optimization and sales productivity: one account manager per product specialist; robust CRM utilization and workflow tools supporting referral management prioritization
  • AffloVest operational/innovation: received FDA 510(k) clearance for next-generation AffloVest with weight reduction, new digital connectivity, improved size adjustability; commercial launch targeted for 2026-2027 winter respiratory season
  • Flexitouch innovation roadmap: patient experience enhancements (new controller, reduced external hosing, remote control via Kylie application) targeting go-to-market readiness in 2027
  • Care navigation pilots: targeted touchpoints to reduce administrative friction and patient leakage; intended to reduce reliance on sales reps over time

AI IconMarket Outlook

  • Full-year 2026 revenue guidance raised to $360M–$368M (+~9% to +~12% YoY)
  • 2026 GAAP gross margin guide: 76%–77%
  • 2026 GAAP operating expenses: increase 10%–12% YoY (increase driven by one-time acquisition and legal-related costs vs prior outlook)
  • 2026 net interest income: ~ $3M; tax rate: 28%; fully diluted weighted average shares: ~22M–23M
  • 2026 adjusted EBITDA: $49M–$51M (includes noncash items: stock comp ~$9M; intangible amortization ~$3.6M; depreciation ~$3.2M; litigation ~$1M; one-time acquisition/integration ~$1.3M)
  • Management framing: early Medicare prior authorization approval/denial outcomes are still maturing; guidance reflects discipline until longer track record

AI IconRisks & Headwinds

  • Early-stage variability across MACs in Medicare prior authorization interpretation/processing; management stated denial/approval rates may differ by region despite identical criteria
  • Potential administrative friction and delays from new prior authorization process (patient face-to-face visit requirement, documentation packet submission, claim status checks)
  • Short-term sequencing risk in Q2/Q3: management expects lighter step-up in Q2 than some past years with normalization later (bigger step-up in Q3)
  • Interest income headwind: interest income decreased $0.2M (-26% YoY) due to decreased cash position
  • Tax normalization uncertainty: Q1 tax expense vs prior-year benefit

Q&A: Analyst Interest

  • Topic: Pull-forward vs order acceleration mechanics and whether Q2 was sacrificed: Management clarified the April 13 go-live acceleration was for patient benefit, not revenue cover. They said orders in process that might have failed by the deadline would otherwise have restarted prior authorization; extra resources ensured completion, with no intentional rebooking of Q2 revenue into Q1.
  • Topic: MAC variability, early approval/denial cadence, and quarterly sequencing implications: Management emphasized the process is only three weeks old and variability between MACs appears administrative (interpretation, data flow, training/education). They expect confidence in true process time and approval rates to rise with experience. For sequencing, Q2 should grow over Q1, but Q2 step-up may be lighter while Q3 normalizes.
  • Topic: Lymphotech contribution timing and longer-term role across 2027+: Management said LIGHT/ GUIDE grants will come through as revenue, explaining why Lymphotech is included in guidance now. They stated Lymphotech is not expected to materially drive this year’s growth. The biggest value is R&D capabilities for next-gen therapy/diagnostics, including future FDA/CPT-driven diagnostic expansion; no specific timelines were provided.

Sentiment: MIXED

Note: This summary was synthesized by AI from the TCMD Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for TCMD.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (TCMD)

© 2026 Stock Market Info — Tactile Systems Technology, Inc. (TCMD) Financial Profile